Quadrant Capital Group’s Cullinan Oncology CGEM Stock Holding History

Quadrant Capital Group’s Portfolio CGEM Stock Details CGEM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$10.8K	Hold	761	–	–	﹤0.01%	2173
2025 Q4	$7.88K	Sell	761 -143	-16%	-$1.29K	﹤0.01%	2265
2025 Q3	$5.36K	Buy	+904	New	+$6.62K	﹤0.01%	2309
2025 Q2	–	Sell	-2,972	Closed	-$22.5K	–	1580
2025 Q1	$22.5K	Buy	2,972 +2,731	+1,133%	+$26.2K	﹤0.01%	2003
2024 Q4	$2.94K	Sell	241 -20	-8%	-$287	﹤0.01%	2442
2024 Q3	$4.37K	Sell	261 -27	-9%	-$479	﹤0.01%	2349
2024 Q2	$5.02K	Sell	288 -18	-6%	-$383	﹤0.01%	2287
2024 Q1	$5.21K	Buy	306 +65	+27%	+$1K	﹤0.01%	2303
2023 Q4	$2.46K	Buy	+241	New	+$2.13K	﹤0.01%	2436
2023 Q1	–	Sell	-631	Closed	-$6.66K	–	2728
2022 Q4	$6.66K	Buy	+631	New	+$7.67K	﹤0.01%	2126

Other funds holding CGEM

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Quadrant Capital Group's CGEM Position: Q1 2026 in Review

Quadrant Capital Group held its Cullinan Oncology (CGEM) position steady in Q1 2026 at 761 shares worth $10.8K. The position accounts for ﹤0.01% of the portfolio, ranked #2173.

Quadrant Capital Group first reported a position in CGEM in Q4 2022 and has held it in 10 quarters since. The position peaked at $22.5K in Q1 2025. 174 funds tracked by Wall St. Rank hold CGEM as of Q1 2026.

Quadrant Capital Group held 761 shares of Cullinan Oncology worth $10.8K as of Q1 2026.
Quadrant Capital Group left its Cullinan Oncology share count unchanged in Q1 2026.
Cullinan Oncology made up ﹤0.01% of Quadrant Capital Group's portfolio in Q1 2026, its #2173 holding.
Quadrant Capital Group first reported a position in Cullinan Oncology in Q4 2022 and has held it in 10 quarters since.
Quadrant Capital Group's Cullinan Oncology position peaked at $22.5K in Q1 2025.
174 funds tracked by Wall St. Rank held Cullinan Oncology as of Q1 2026.

Based on Quadrant Capital Group's 13F filing for Q1 2026, filed 11 May 2026.